COLOPLAST LIMITED

1. COLOPLAST LIMITED 1978-12-31 → present
2. COLOPLAST UK MEDICAL SUPPLIES LIMITED 1973-02-05 → 1978-12-31

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The UK business continues to thrive, with continued growth. We have a robust supply chain, and we expect no adverse impact on cash flow. We continue to receive the backing of our parent company, Coloplast A/S, where the UK continues to be a significant contributor to the group's results. Accordingly, we continue to adopt the going concern basis in preparing the financial statements. In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of twelve months from when the financial statements are authorised for issue.”

Group structure

1. COLOPLAST LIMITED · parent
   1. Charter Healthcare Limited 100% · UK · dormant
   2. Coloplast Medical Limited 100% · UK · dormant

Significant events

• “Turnover grew 5% to £390,449,000 (2023: £371,575,000) broadly in line with the prior year's growth. We have seen continued growth across our product lines and increased market share on our Coloplast Charter Service.”
• “Net assets decreased to £48,591,000 (2023: £73,895,000), mainly driven by an increase in our liabilities as a result of intercompany creditor balances.”
• “The MedTech Directorate is working to improve the MedTech environment and patient/NHS outcomes. This involves consultations on improving accessibility of information and categorising products for clinicians' use of Part IX products, and NICE Late-Stage Assessment process on Colostomy Bags, ISC and Anti-microbial dressings.”
• “Coloplast A/S was included on the Global 100 list by Corporate Knights in 2024 - ranked as no. 1 within Medical Equipment Manufacturing and as no. 78 overall.”
• “Coloplast UK has been awarded an 'Outstanding' inspection rating the highest rating possible from the Care Quality Commission (CQC) for its nursing and telehealth service.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +5.1%

  £371,575,000 → £390,449,000

• Cash

  0%

  £1,000 → £1,000

• Net assets

  -34.2%

  £73,895,000 → £48,591,000

• Employees

  +6.5%

  673 → 717

• Operating profit

  -7.6%

  £31,874,000 → £29,454,000

• Profit before tax

  -6.4%

  £33,985,000 → £31,808,000

• Wages

  +8.8%

  £31,919,000 → £34,725,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers